The Royal College of Psychiatrists (RCPsych) has endorsed ketamine-based medication for treating depression in clinical settings, while urging more research into other psychedelic drugs.
Experts deemed it "vital" to develop new mental health treatments, but warned against claims around psychedelics "jumping ahead of the evidence," stressing that "hype" must not be "prioritised above good clinical practice."
